
Profound Medical Corp PRN.TO is expected to show a rise in quarterly revenue when it reports results on May 8 for the period ending March 31 2025
The Mississauga Ontario-based company is expected to report a 62.3% increase in revenue to $3.1 million from $1.91 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Profound Medical Corp is for a loss of 29 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 3.7% in the last three months.
Wall Street's median 12-month price target for Profound Medical Corp is $11.75, above its last closing price of $4.96.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.30 | -0.32 | -0.20 | Beat | 38 |
Sep. 30 2024 | -0.31 | -0.30 | -0.38 | Missed | -25.6 |
Jun. 30 2024 | -0.28 | -0.29 | -0.28 | Beat | 2.3 |
Mar. 31 2024 | -0.31 | -0.30 | -0.26 | Beat | 14.1 |
Dec. 31 2023 | -0.28 | -0.32 | -0.42 | Missed | -32.6 |
Sep. 30 2023 | -0.33 | -0.33 | -0.26 | Beat | 21.7 |
Jun. 30 2023 | -0.35 | -0.34 | -0.35 | Missed | -2.5 |
Mar. 31 2023 | -0.35 | -0.34 | -0.32 | Beat | 6.7 |
This summary was machine generated May 6 at 23:03 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)